Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in 2023. Its unique evaporation-inhibiting effect provides a new option for patients with dry eye syndrome.

How to Purchase Perfluorohexyl Octane Eye Drops (Miebo)

Overseas Purchase

Patients can choose to visit hospital pharmacies or formal drugstores in countries or regions where Perfluorohexyl Octane Eye Drops have been launched to consult and purchase the drug.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan well before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Perfluorohexyl Octane Eye Drops (Miebo)

Strictly Follow Medication Guidance

Dosage and Frequency: Administer 1 drop into the affected eye 4 times a day. Do not arbitrarily increase or decrease the dosage.

Contact Lens Use: Remove contact lenses before instilling the eye drops, and wait for at least 30 minutes after medication before reinserting them.

Operation Specifications: Follow the steps in the instruction manual - after opening the bottle, keep it upright and squeeze gently, invert the bottle and release to draw in air, then squeeze again to instill the drops into the eye.

Medication Warnings for Special Populations

Allergy Contraindication: Patients who are allergic to perfluorohexyl octane are strictly prohibited from using this drug. Clinical trials have shown that hypersensitivity reactions are one of the main adverse reactions.

Pregnant and Lactating Women: Animal experiments have shown that rabbits experienced miscarriage and reduced fetal weight after using this drug. There is insufficient research data on human pregnant women, so the use of this drug requires a strict assessment of benefits and risks.

Children and Elderly People: The safety of this drug in people under 18 years old has not been verified. Although no specific risks have been found in the elderly when using this drug, individualized monitoring is still required.

Adverse Reaction Monitoring

Clinical data shows that approximately 1-3% of users experience reactions such as blurred vision and conjunctival hyperemia.

It is recommended to closely observe the eye condition after the first use of the drug. If persistent discomfort or allergic symptoms occur, stop using the drug immediately and contact a doctor.

Identification of Authenticity of Perfluorohexyl Octane Eye Drops (Miebo)

Packaging Information Verification

The authentic product packaging box is printed with the NDC code and the Bausch & Lomb corporate logo.

The bottle is labeled "100% Perfluorohexyl Octane", with a capacity of 5mL in a multi-dose polypropylene bottle, and the solution is colorless and transparent.

If the liquid is turbid, discolored, or the packaging is damaged, the product should be rejected and reported.

Physical Property Verification

The density of the authentic solution is 1.338g/mL. It is almost insoluble in water but miscible with ethanol.

Verification can be done by shaking: after inverting the authentic product, a stable interface will form due to surface tension, while counterfeit products often show abnormal stratification due to differences in ingredients.